Haemonetics Beats Analyst Estimates on EPS
Haemonetics (NYS: HAE) reported earnings on Jan. 30. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q3), Haemonetics beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew, and GAAP earnings per share dropped significantly.
Margins contracted across the board.
Haemonetics booked revenue of $191.2 million. The seven analysts polled by S&P Capital IQ predicted sales of $184.3 million. Sales were 8.1% higher than the prior-year quarter's $176.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.
Non-GAAP EPS came in at $0.86. The eight earnings estimates compiled by S&P Capital IQ averaged $0.80 per share on the same basis. GAAP EPS of $0.72 for Q3 were 6.5% lower than the prior-year quarter's $0.77 per share.
Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.
For the quarter, gross margin was 50.2%, 270 basis points worse than the prior-year quarter. Operating margin was 13.2%, 300 basis points worse than the prior-year quarter. Net margin was 9.5%, 170 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $183 million. On the bottom line, the average EPS estimate is $0.87.
Next year's average estimate for revenue is $717.6 million. The average EPS estimate is $3.05.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 120 members out of 123 rating the stock outperform, and three members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 43 give Haemonetics a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Haemonetics is hold, with an average price target of $67.13.
Over the decades, small-cap stocks, like Haemonetics have provided market-beating returns, provided they're value priced and have solid businesses. Read about a pair of companies with a lock on their markets in "Too Small to Fail: Two Small Caps the Government Won't Let Go Broke." Click here for instant access to this free report.
- Add Haemonetics to My Watchlist.
At the time this article was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.